UNSPSC 51313120: Levocetirizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SOD6A38AGA. European Medicines Agency schedules Levocetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20474. Levocetirizine dihydrochloride generally arises in the molecular formula C21H25CLN2O3.2CLH. The term 'levocetirizine dihydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule levocetirizine dihydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, LEVOCETIRIZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levocetirizine dihydrochloride bears US NLM identifiers UMLS ID C1311681 and NCI Concept Code C72814. SMILES: C1CCC(CC1)[C@H](C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.

UNSPSC 51313120 Levocetirizine dihydrochloride is a Commodity code for pharmaceutical products, though the recent state and local procurement activity under this code shows a significant mismatch: the only recorded opportunity involves naloxone and drug deactivation systems rather than levocetirizine, an over-the-counter antihistamine. State and local governments procuring under this code nominally purchase individual pharmaceutical active ingredients or finished-goods medications for public health programs, emergency medical response, or community health initiatives. The issuing bodies for pharmaceutical procurement span county health departments, public safety agencies, and integrated community health systems. Vendors must typically comply with drug-free workplace certification, E-Verify requirements, and when FEMA funding is involved, federal environmental and procurement regulations.

Seminole County, Florida posted the only recent opportunity under this code: IFB 60459723LAS, released June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023, at 2:00 pm. The contract carries a two-year initial term with a one-year renewal option, includes a three-month probationary termination clause, and requires vendors to cover all shipping and delivery costs. The procurement does not name explicit set-aside designations and carries potential FEMA funding with associated federal compliance obligations. The narrow activity under this specific code suggests either infrequent levocetirizine procurement at the state and local level or consistent miscoding of pharmaceutical opportunities in procurement systems; business development professionals should verify the actual pharmaceutical product needed before bid preparation.